` CSHLPress.com - nuclear pores cell cancer

CSHL Press News

Tweaking cells’ gatekeepers could lead to new way to fight cancer

09/18/2018

Tweaking cells’ gatekeepers could lead to new way to fight cancer

Salk scientists develop method to manipulate numbers of nuclear pores

LA JOLLA—If the cell nucleus is like a bank for DNA, nuclear pores are the security doors around its perimeter. Yet more security doors aren’t necessarily better: some cancer cells contain a dramatic excess of nuclear pores.

Tweaking cells’ gatekeepers could lead to new way to fight cancer.
Tweaking cells’ gatekeepers could lead to new way to fight cancer.

Click here for a high-resolution image.

Credit: Salk Institute

Salk Institute researchers reported on September 18, 2018, in the journal Genes & Development that they have devised a way to manipulate numbers of individual nuclear pores—a breakthrough that may one day stop cancerous cells from proliferating out of control.

“Previously, we didn’t have the tools to artificially increase nuclear pores,” says lead author Martin Hetzer, who is also Salk’s vice president and chief science officer. “Our study provides an experimental avenue to ask critical questions: What are the consequences of boosting the number of nuclear pores in a healthy cell to mimic those found in a cancer cell? Does this affect gene activity? Why do cancer cells increase the number of nuclear pores?”

Nuclear pores are essential elements of all cells that provide controlled ways to move cellular material in and out of a nucleus. In organisms ranging from fungi to mammals, individual cells possess these transport channels that mediate a thousand events per second. Individual nuclear pores are fashioned from multiple copies of 30 proteins known as nucleoporins. Hetzer and colleagues looked at the nucleoporin Tpr, which has been implicated in certain cancers.

The team showed, for the first time, that each of the transport channels within a cell is unique, and each cell nucleus possesses a specific number of nuclear pores. Next, the team used molecular methods to remove Tpr to see its effect on the number of nuclear pores, with a surprising result.

Cells with the Tpr protein (top row) have fewer nuclear pores than cells without the protein (bottom row). The right column shows a close-up of the pore density, with many more pores appearing in the absence of Tpr (bottom left).
Cells with the Tpr protein (top row) have fewer nuclear pores than cells without the protein (bottom row). The right column shows a close-up of the pore density, with many more pores appearing in the absence of Tpr (bottom left).

Click here for a high-resolution image.

Credit: Salk Institute

“Typically, when you ‘knock down’ or remove some of the proteins that make up the nuclear pore complex, the total number of nuclear pores goes down,” says Asako McCloskey, first author of the paper and a Salk research associate. “Our surprising finding was that when we get rid of the nucleoporin Tpr, nuclear pore numbers went up dramatically.”

“This is the first time that modifying a component within the transport channel has been shown to increase the number of nuclear pores,” adds Hetzer.

This indicates that Tpr plays a role not in transport itself, but in regulating the assembly of nuclear pores. The knowledge could be crucial for future attempts to manipulate numbers of nuclear pores to treat disease. For example, cells with higher metabolic activity—such as stimulated thyroid follicular cells or aggressive tumors—have more nuclear pores per nucleus. Other research has shown that stopping cancer-related “cargo” proteins from being transported through the nuclear pores can lead to dramatic effects in cancer treatment. Targeting nuclear pores could also negate aggressive cancer’s resistance to multiple drugs, as higher numbers of nuclear pores in tumor cells allow them to export chemotherapy out of the nuclei.

Next, the lab will use the new technique to pinpoint the effects of tweaking nuclear pore numbers in a variety of cell types.

The paper’s other author is Arkaitz Ibarra, a scientist at Molecular Stethoscope in San Diego.

The work was funded by the National Institutes of Health, the Helmsley Center for Genomic Medicine, the Nomis Foundation and the Glenn Center for Aging Research.

PUBLICATION INFORMATION

JOURNAL

Genes & Development

AUTHORS

Martin Hetzer, Asako McCloskey and Arkaitz Ibarra



Return to CSHL Press News index